NRC FORM 374
(7-94)

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 60

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

302676

Licensee	
1. St. Luke's Hospital of Kansas City 2. 4401 Wornall Road Kansas City, MO 64111	In accordance with the letter dated May 9, 1997 3. License Number 24-00889-01 is amended in its entirety as follows: 4. Expiration Date February 28, 2002 5. Docket or Reference No. 030-02286

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed (not to exceed 1 curie of I-131)
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy sources identified in 10 CFR 35.400	D. As needed
E. Cesium-137	E. Sealed sources (International CIS Model No. CEA-ORIS-LAPIB Model 437C)	E. 5,100 curies total (3 sources not to exceed 1,700 curies each)
F. Phosphorus-32	F. Prepackaged Kits	F. 10 millicuries
G. Sulfur-35	G. Prepackaged Kits	G. 10 millicuries
H. Hydrogen-3	H. Any	H. 100 millicuries
I. Carbon-14	I. Any	I. 100 millicuries

180305
9706190071 970609
PDR ADOCK 03002286
C PDR

COPY

Printed on recycled paper

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-00889-01

Docket or Reference Number
030-02286

Amendment No. 60

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

C. Medical use described in 10 CFR 35.300.

D. Medical use described in 10 CFR 35.400.

E. To be used in an International CIS Model IBL-437C irradiator for the irradiation of blood, blood products, cells, tissues and research samples, excluding explosives or highly flammable materials.

F. and G. To be used for in-vitro laboratory studies.

H. and I. For human research.

CONDITIONS

10. A. Licensed materials in Item Nos. 6.A., 6.B., 6.C., 6.D. and 6.E. shall be used at the licensee's facilities located at St. Luke's Hospital of Kansas City, 4401 Wornall Road, Kansas City, Missouri.

B. Licensed materials in Item Nos. 6.F. and 6.G. shall be used at the licensee's facilities located at the Dickson-Diveley Laboratory, 4312 J.C. Nichols Parkway, Kansas City, Missouri.

C. Licensed materials in Item Nos. 6.H. and 6.I. shall be used at the licensee's facilities located at the Medical Plaza I Building, 4320 Wornall Road, Kansas City, Missouri.

11. Radiation Safety Officer: John C. Erb, Ph.D.

12. A. Licensed material listed in Items 6.A. through 6.D. above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
Timothy M. Bateman, M.D.	10 CFR 35.200 for cardiovascular clinical procedures

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-00889-01

Docket or Reference Number
030-02286

Amendment No. 60

12. (Continued)

Authorized Users	Material and Use
Thomas L. Rosamond, M.D.	10 CFR 35.200 for cardiovascular clinical procedures
Michelle L. Pal, M.D.	10 CFR 35.100 and 35.200
James G. Fitzsimmons, M.D.	10 CFR 35.100, 35.200 and 35.300
Bertrand L. Gallet, M.D.	10 CFR 35.100, 35.200 and 35.300
Kenneth M. Jacob, M.D.	10 CFR 35.100, 35.200 and 35.300
Christie B. Phelan, M.D.	10 CFR 35.100, 35.200 and 35.300
Arthur Elman, M.D.	10 CFR 35.400
Robyn Hart, M.D.	10 CFR 35.400
R. Bruce Hoskins, M.D.	10 CFR 35.400
Mark L. Redick, Ph.D., M.D.	10 CFR 35.100, 35.200 and 35.300
Pablo N. Delgado, M.D.	10 CFR 35.100, 35.200 and 35.300

B. Licensed material listed in Item 6.E. above is only authorized for use by John C. Erb, Ph.D. or Mollye B. Norris, BSRT, CMD.

C. Licensed material listed in Items 6.F. and 6.G. above is only authorized for use by Nabih I. Abdou, M.D., Ph.D.

D. Licensed material listed in Items 6.H and 6.I. above is only authorized for use by John Miles, M.D.

13. A. Sealed sources and detector cells shall be tested for leakage and/or contamination at intervals not to exceed six months or at such other intervals as specified by the certificate of registration referred to in 10 CFR 32.210.

COPY

License Number
24-00889-01

Docket or Reference Number
030-02286

Amendment No. 60

MATERIALS LICENSE
SUPPLEMENTARY SHEET

13. (Continued)

B. In the absence of a certificate from a transferor indicating that a leak test has been made within six months prior to the transfer, a sealed source or detector cell received from another person shall not be put into use until tested.

C. Sealed sources need not be leak tested if:

(i) they contain only hydrogen-3; or

(ii) they contain only a radioactive gas; or

(iii) the half-life of the isotope is 30 days or less; or

(iv) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or

(v) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than ten years without being tested for leakage and/or contamination.

D. The leak test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(b)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region III, ATTN: Chief, Nuclear Materials Safety Branch, 801 Warrenville Road, Lisle, Illinois 60532-4351. The report shall specify the source involved, the test results, and corrective action taken.

E. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically licensed by the Commission or an Agreement State to perform such services.

COPY

License Number
24-00889-01

Docket or Reference Number
030-02286

Amendment No. 60

MATERIALS LICENSE
SUPPLEMENTARY SHEET

14. The licensee shall not perform repairs or alterations of the irradiator involving removal of shielding or access to the licensed material. Removal, replacement, and disposal of sealed sources in the irradiator shall be performed by a person specifically licensed by the Commission or an Agreement State to perform such services.

15. The procedures contained in the International CIS instruction manual for the Model IBL-437C device shall be followed and a copy of this manual shall be made available to each person using or having responsibility for the use of the device.

16. The licensee shall conduct a physical inventory every six months to account for all sources and/or devices received and possessed under the license.

17. The licensee shall not use licensed material in or on human beings except as provided otherwise by specific condition of this license.

18. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.

19. The licensee is authorized to hold radioactive material with a physical half-life of less than 90 days for decay-in-storage before disposal in ordinary trash provided:

    A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.

    B. Before disposal as ordinary trash, byproduct material shall be surveyed at the container surface with the appropriate survey meter set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

    C. A record of each disposal permitted under this License Condition shall be retained for three years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.

20. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

COPY

License Number
24-00889-01

Docket or Reference Number
030-02286

Amendment No. 60

MATERIALS LICENSE
SUPPLEMENTARY SHEET

21. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application dated November 14, 1994; and

    B. Letters dated June 13, 1996, June 14, 1996, July 18, 1996, July 31, 1996, January 2, 1997 and January 27, 1997.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUN 09 1997

By Evelyn R. Meter
Nuclear Materials Licensing Branch, Region III

COPY

JUN 0 9 1997

John C. Erb, Ph.D.
Radiation Safety Officer
St. Luke's Hospital of Kansas City
4401 Wornall Road
Kansas City, MO 64111-3220

Dear Dr. Erb:

Enclosed is Amendment No. 60 to your NRC Material License No. 24-00889-01 in accordance with your request.

Review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office so that we can provide appropriate corrections and answers.

Please be advised that your license expires at the end of the day, in the month, and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.

2. Notify NRC, in writing, within 30 days:

   a. When an authorized user or Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change; or

   b. When the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).

3. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license:

   a. When you decide to terminate all activities involving materials authorized under the license; or

302676

b. If you decide not to complete the facility, acquire equipment, or possess and use authorized material.

4. Request and obtain a license amendment before you:

a. Receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this Part;

b. Permit anyone, except individuals described in 10 CFR 35.13(b) to work as an authorized user under the license;

c. Change Radiation Safety Officers;

d. Order byproduct material in excess of the amount, or radionuclide, or form different than authorized on the license;

e. Add or change the areas of use or address or addresses of use identified in the license application or on the license; or

f. Change ownership of your organization.

5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Policy and Procedures for NRC Enforcement Actions, 10 CFR Part 2, Appendix C.

Since serious consequences to employees and the public can result from failure to comply with NRC requirements, prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

Sincerely,

Original Signed By
Evelyn R. Matson
Nuclear Materials Licensing Branch

License No.: 24-00889-01
Docket No.: 030-02286

Enclosure: Amendment No. 60

DOCUMENT NAME: M:\03002286.CL7

To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" = Copy with attachment/enclosure "N" = No copy

OFFICE	DNMS/RIII					
NAME	ERMatson:brt					
DATE	06/6/97					

OFFICIAL RECORD COPY

UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION III
801 WARRENVILLE ROAD
LISLE, ILLINOIS 60532-4351

May 30, 1997

John C. Erb, Ph.D.
Radiation Safety Officer
St. Luke's Hospital of Kansas City
4401 Wornall Road
Kansas City, MO 64111-3220

SUBJECT: ACKNOWLEDGEMENT OF CORRESPONDENCE
(Letter Dated 05/09/97)

Dear Licensee:

In response to your request, we have completed the initial processing, which is an administrative review of your application for a(n):

___ New License X Amendment ___ Renewal
___ Termination ___ Auth User (Amendment not required)
___ Other_____

No administrative deficiencies were identified during this initial review. However, it should be noted that a technical review may identify omissions in the submitted information.

It appears that your request is routine (see 1-3 below, as applicable).

1. New and amendment actions are normally processed within 90 days, unless we find major deficiencies, or policy issues requiring central program office assistance.

2. Renewal actions are normally processed within 180 days, however, under timely filing (before expiration), you may continue to operate under your existing license.

3. Termination actions are normally processed within 90 days, unless confirmatory surveys following decontamination/decommissioning activities are involved.

A copy of your correspondence has been forwarded to our Licensing Fee and Debt Collection Branch (301/415-6097) for approval of the fee category and amount, if required.

If you have a compelling safety or business-related reason for requesting expedited review, please contact the Materials Licensing Branch at (630) 829-9887. We will try to complete your request as soon as practicable. Any correspondence about this request should reference the control number.

Nuclear Materials Support Branch

Mail Control No. 302676
License No. 24-00889-01

R9

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)
INFORMATION FROM LTS

Program Code: 02120
Status Code: 0
Fee Category: 7C 3E
Exp. Date: 20020228
Fee Comments: 3E EFF 08/13/96
Decom Fin Assur Reqd: N

1997 JUN -2 AM 11:45

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
Applicant/Licensee: ST. LUKE'S HOSPITAL OF KANSAS CITY
Received Date: 970527
Docket No: 3002286
Control No.: 302676
License No.: 24-00889-01
Action Type: Amendment

2. FEE ATTACHED
Amount: 440
Check No.: 544604

3. COMMENTS

Signed D. Hersey
Date 5-30-97

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered ✓)

1. Fee Category and Amount: 7C 3E $440

2. Correct Fee Paid. Application may be processed for:
Amendment ✓
Renewal
License

3. OTHER

Signed SC
Date 6/2/97

JUN 05 1997

Log June 1 III
Remitter
Check No. 544604
Amount $440
Fee Category 7C 3E
Type of Fee AMD
Date Check Rec'd 6/2/97
Date Completed
By: SC

Saint Luke's Hospital of Kansas City
SAINT LUKE'S-SHAWNEE MISSION HEALTH SYSTEM

Winner
1997 National Quality Health Care Award

DATE: May 09, 1997

TO: U.S. Nuclear Regulatory Commission
Region III Office
Nuclear Materials Licensing Branch
801 Warrenville Road
Lisle, IL 60532-4351

SUBJ: Amendment Request to NRC License No. 24-00889-01, Docket No. 030-02286, to allow Mark L. Redick, M.D. and Pablo N. Delgado, M.D. as Authorized Users for 10 CFR 35, Subpart F, *Radiopharmaceuticals for Therapy*

FROM: John C. Erb, Ph.D.
St. Luke's Hospital of Kansas City
Department of Radiation Therapy
4401 Wornall Road
Kansas City, MO 64111-3220
Phone: 816-932-2575
Fax: 816-932-2344

Request that our NRC License No. 24-00889-01 be amended to designated Mark L. Redick, M.D. and Pablo N. Delgado, M.D. as Authorized Users under 10 CFR 35, Subpart F, *Radiopharmaceuticals for Therapy*. Both Dr. Redick and Dr. Delgado are certified in Diagnostic Radiology by the American Board of Radiology (ABR); copies of their credentials are attached.

Also, please note that the U.S. Postal Service has requested that the street address of St. Luke's Main Hospital be changed from "Wornall Road at Forty-Fourth" to that given above.

John C. Erb
John C. Erb, Ph.D.
Radiation Safety Officer

9 Attachments
1. ABR Certification for Dr. Redick
2. NRC Form 313, Supplements A & B for Dr. Redick
3. Medical State License for Dr. Redick
4. RSC Appointment Letter as Authorized User for Parts 100 & 200 for Dr. Redick
5. ABR Certification for Dr. Delgado
6. NRC Form 313, Supplements A & B for Dr. Delgado
7. Medical State License for Dr. Delgado
8. RSC Appointment Letter as Authorized User for Parts 100 & 200 for Dr. Delgado
9. Check of $440.00 for amendment fee

RECEIVED
MAY 27 1997
REGION III

JUN 05 1997

4401 Wornall Road, Kansas City, MO 64111 • (816) 932-2000

Saint Luke's-Shawnee Mission Health System is an Equal Employment Opportunity Employer / Services Provided on a Nondiscriminatory Basis.

302676

C. Douglas Maynard, M.D., President
Sarah S. Donaldson, M.D., Vice President
William J. Casarella, M.D., Secretary-Treasurer
David G. Bragg, M.D.
Robert E. Campbell, M.D.
Edward L. Chaney, M.D.
Gerald D. Dodd, M.D.
Thomas S. Harle, M.D.
Jay R. Harris, M.D.
Robert R. Hattery, M.D.

The American Board of Radiology

M. Paul Capp, M.D., Executive Director

Assistant Executive Directors
Robert E. Campbell, M.D., Diagnostic Radiology
Lawrence W. Davis, M.D., Radiation Oncology

5255 E. Williams Circle
Suite 6800
Tucson, Arizona 85711

Phone (520) 790-2900
Fax (520) 790-3200

William R. Hendee, Ph.D.
David H. Hussey, M.D.
George R. Leopold, M.D.
John E. Madewell, M.D.
Rodney R. Million, M.D.
Carlos A. Perez, M.D.
Andrew K. Poznanski, M.D.
Helen C. Redman, M.D.
Joseph F. Sackett, M.D.
Isaac Sanders, M.D.
Melvyn H. Schreiber, M.D.
Guy H. Simmons, Ph.D.
H. Rodney Withers, M.D.
James E. Youker, M.D.

November 6, 1995

MARK LANKFORD REDICK, PHD,MD
5448 ABERDEEN
FAIRWAY, KS 66205

39285 / DR / 17 / 124

Dear Doctor Redick:

I am pleased to inform you that you passed the oral examination held November 6-7, 1995. The American Board of Radiology grants you its Certificate of Diagnostic Radiology.

The certificate will be sent via UPS to the above address in approximately three months. Your name will appear on the certificate as shown above. If you wish your name to appear differently, please notify the Board office within thirty days.

Your name will be included in a Directory published by The American Board of Medical Specialties unless you specify otherwise in writing to the ABMS. It is your responsibility to notify your local and state medical organizations of your certification.

On behalf of the Board of Trustees of The American Board of Radiology, I congratulate you on this achievement.

Sincerely,

M. Paul Capp, M.D.

EXHIBIT 2

SUPPLEMENT A

SUPPLEMENT

U.S. NUCLEAR REGULATORY COMMISSION

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER: Dr. Mark Redick

2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED:

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
American Board of Radiology	Diagnostic Radiology	11/95

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATES OF TRAINING B	TYPE AND LENGTH OF TRAINING: CLOCK HOURS IN LECTURE OR LABORATORY	CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE
a. RADIATION PHYSICS AND INSTRUMENTATION	University of Kansas Medical Center Jan - April 1992	60	50+
b. RADIATION PROTECTION	University of Kansas Medical Center Jan - April 1992	10	10+
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	University of Kansas Medical Center Jan - April 1992	15	10+
d. RADIATION BIOLOGY	University of Kansas Medical Center Jan - April 1992	20	—
e. RADIOPHARMACEUTICAL CHEMISTRY	University of Kansas Medical Center Oct - Jan 1995	52	20+

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	mCi USED AT ONE TIME	LOCATION	CLOCK HOURS	TYPE OF USE
Tc-99m	30 mCi	University of Kansas Medical Center		medical imaging
Ga-67	10 mCi	"		"
In-111	1 mCi	"		"
I-131	150 mCi	"		thyroid cancer Tx
Sr-89	5 mCi	"		bone metastasis Tx

EXHIBIT 3

SUPPLEMENT B

SUPPLEMENT

U. S. NUCLEAR REGULATORY COMMISSION

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS

FULL NAME: Mark L. Redick

STREET ADDRESS: 5448 Absaraka

CITY: Fairway STATE: Ks ZIP CODE: 66205

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD INCLUDE OF:

1. Supervised examination of patients to determine the suitability for radiopharmaceuticals diagnostic and/or treatment and recommendation for dosage and route.
2. Collaboration in dose calculation and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
3. Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnostic and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheet.) D
	Thyroid scan	119	
	Thyroid uptake	89	
	Lung perfusion scan	415	
	Xenon ventilation study	374	
	Aerosol ventilation scan	0	
	Renal flow scan	317	
	Brain scan	189	
	Liver/spleen scan	6	
	Bone scan	945	
	Gallbladder/biliary study	3	
	Leakage shunt study	7	
	Cystogram	0	
	Sequestrogram	1	
	Cardiac perfusion scan	490	
	Cardiac stress ventriculogram	74	
	Cardiac rest ventriculogram	379	
	Gallium scan	178	

EXHIBIT 3 (Continued)

PROPOSED PHYSICIAN USER
Mark Redick MD

PRECEPTOR STATEMENT (Continued)

B. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheet.) D
P-32 (Colloid)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	2	
P-32 (Colloid)	INTRACAVITARY TREATMENT	0	
I-131	TREATMENT OF THYROID CARCINOMA	23	
	TREATMENT OF HYPERTHYROIDISM	48	
Au-198	INTRACAVITARY TREATMENT	0	
Co-60 or Cs-137	INTERSTITIAL TREATMENT	0	
	INTRACAVITARY TREATMENT	0	
I-125 or Ir-192	INTERSTITIAL TREATMENT	0	
Co-60 or Cs-137	TELETHERAPY TREATMENT	0	
Cr-51	TREATMENT OF EYE DISEASE	0	
	RADIOPHARMACEUTICAL PREPARATION	45	
Mo-99/Tc-99m	GENERATOR	10	
Sn-113/In-113m	GENERATOR	0	
Tc-99m	REAGENT KITS	45	
Other	Sr-89	53	for metastatic bone disease
	Tc-99m sulfur colloid	13	for lymph node scans
	In-111 DTPA	11	cisternograms

C. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

LOCATION	DATES	CLOCK HOURS OF EXPERIENCE
University of Kansas Medical Center	July 1995 - June 1996	1700+

D. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

1. NAME OF SUPERVISOR: Kirkman G. Baxter, M.D.
2. NAME OF INSTITUTION: University of Kansas Medical Center
3. MAILING ADDRESS: 3901 Rainbow Blvd.
4. CITY: Kansas City, KS 66160
5. REFERENCE LICENSE NUMBER: 18-C054-02

6. PRECEPTOR'S SIGNATURE: Kirkman G. Baxter MD
7. PRECEPTOR'S NAME (Print or type): Kirkman G. Baxter, M.D.
8. DATE: 2/4/97

01118229

State of Missouri

Department of Economic Development
Division of Professional Registration
Board of Registration for the Healing Arts

PHYSICIAN AND SURGEON

VALID THROUGH JANUARY 31, 1998
ORIGINAL CERTIFICATE/LICENSE NO. MD 111830

ISSUED: 10/31/96

MARK L REDICK M.D.
5448 ABERDEEN
FAIRWAY KS 66205

Tina Steinman
EXECUTIVE DIRECTOR

Randall G Singer
DIVISION DIRECTOR

Saint Luke's Hospital of Kansas City
SAINT LUKE'S-SHAWNEE MISSION HEALTH SYSTEM

Winner
1997 National Quality Health Care Award

April 10, 1997

TO: Memorandum for Record

SUBJ: Approval of Mark L. Redick, M.D. as an Authorized User for Parts 100 & 200

The Radiation Safety Committee has reviewed Dr. Redick's qualifications as specified in 10 CFR 35, Parts 910, *Training for uptake, dilution, and excretion studies*, and 920, *Training for imaging and localization studies*.

Based on his ABR certification in Diagnostic Radiology, and his State of Missouri Medical License (expires Jan 31, 1998), Dr. Redick is hereby approved as an authorized user for Parts 100 and 200.

Approval of Dr. Redick for Part 300, *Use of radiopharmaceuticals for therapy*, must be done through a license amendment. In the interim, Dr. Redick's use of isotopes specified in Part 300 must be done under the supervision of an authorized user who is approved for Part 300. (Note: Orders or Written Directives for Part 300 use must be countersigned.)

A copy of this approval along with documentation of Dr. Redick's qualifications must be forwarded to the NRC.

JAMES G. FITZSIMMONS, M.D.
Chairman, Radiation Safety Committee

users.sam

4401 Wornall Road, Kansas City, MO 64111 • (816) 932-2000

Saint Luke's-Shawnee Mission Health System is an Equal Employment Opportunity Employer / Services Provided on a Nondiscriminatory Basis.

President
Sarah S. Donaldson, M.D.,
Vice President
William J. Casarella, M.D.,
Secretary-Treasurer
David G. Bragg, M.D.
Robert E. Campbell, M.D.
Edward L. Chaney, M.D.
Gerald D. Dodd, M.D.
Thomas S. Harle, M.D.
Jay R. Harris, M.D.
Robert R. Hattery, M.D.

The American Board of Radiology

M. Paul Capp, M.D., Executive Director

Assistant Executive Directors
Robert E. Campbell, M.D., Diagnostic Radiology
Lawrence W. Davis, M.D., Radiation Oncology

5255 E. Williams Circle
Suite 6800
Tucson, Arizona 85711

Phone (520) 790-2900
Fax (520) 790-3200

William E. Hendee, Ph.D.
David H. Hussey, M.D.
George R. Leopold, M.D.
John E. Madewell, M.D.
Rodney R. Million, M.D.
Carlos A. Perez, M.D.
Andrew K. Poznanski, M.D.
Helen C. Redman, M.D.
Joseph F. Sackett, M.D.
Isaac Sanders, M.D.
Melvyn H. Schreiber, M.D.
Guy H. Simmons, Ph.D.
H. Rodney Withers, M.D.
James E. Youker, M.D.

November 7, 1995

PABLO NESTOR DELGADO, MD
3000 BISSONNET, #8206
HOUSTON, TX 77005

38035 / DR / 17 / 211

Dear Doctor Delgado:

I am pleased to inform you that you passed the oral examination held November 6-7, 1995. The American Board of Radiology grants you its Certificate of Diagnostic Radiology.

The certificate will be sent via UPS to the above address in approximately three months. Your name will appear on the certificate as shown above. If you wish your name to appear differently, please notify the Board office within thirty days.

Your name will be included in a Directory published by The American Board of Medical Specialties unless you specify otherwise in writing to the ABMS. It is your responsibility to notify your local and state medical organizations of your certification.

On behalf of the Board of Trustees of The American Board of Radiology, I congratulate you on this achievement.

Sincerely,

M. Paul Capp, M.D.

EXHIBIT 2

SUPPLEMENT A

SUPPLEMENT — U.S. NUCLEAR REGULATORY COMMISSION

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER	2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED
Pablo N. Delgado, M.D.	Missouri/Kansas

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
DIAGNOSTIC RADIOLOGY		

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING: CLOCK HOURS IN LECTURE OR LABORATORY	TYPE AND LENGTH OF TRAINING: CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE
a. RADIATION PHYSICS AND INSTRUMENTATION	BASIC SCIENCE COURSE RADIOLOGY PROGRAM KANSAS UNIV. MED. CNTR	25	7
b. RADIATION PROTECTION	"	10	7
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	"	10	7
d. RADIATION BIOLOGY	"	9	7
e. RADIOPHARMACEUTICAL CHEMISTRY	"	2	7

5. EXPERIENCE WITH RADIATION. *(Actual use of Radioisotopes or Equivalent Experience)*

ISOTOPE	mCi USED AT ONE TIME	LOCATION	CLOCK HOURS	TYPE OF USE
I131	200 mCi	KUMC	10	Therapy CA
Tc99m	30 mCi	KUMC	100	THYROID
Tl201	4 mCi	KUMC	50	Tagged WBC Bone
Sr89	4 mCi	KUMC	10	Myocardial perfusion
In111	4 mCi	KUMC	5	Rx Bone Mets
I131	300 mCi	KUMC	10	Colon Cancer
Ga67	10 mCi	KUMC	10	Thyroid Tumor

EXHIBIT 3

SUPPLEMENT B

SUPPLEMENT

U. S. NUCLEAR REGULATORY COMMISSION

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS

FULL NAME: Pablo N. Delgado, M.D.

STREET ADDRESS: 5641 Aberdeen

CITY: Fairway STATE: KS ZIP CODE: 66205

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted on duplicate or separate sheet.) D
	Thyroid scan	10	
	Thyroid uptake	10	
	Lung perfusion scan	30	
	Xenon ventilation study	30	
	Aerosol ventilation scan	Ø	
	Renal flow scan	30	
	Brain scan	21	
	Liver/spleen scan	7	
	Bone scan	212	
	Gastroesophageal study	12	
	Leveen shunt study	1	
	Cystogram	1	
	Dacryocystogram	1	
	Cardiac perfusion scan.	25	
	Cardiac stress ventriculogram	10	
	Cardiac rest ventriculogram	15	
	Gallium scan	21	

EXHIBIT 3 (Continued)

PROPOSED PHYSICIAN USER
Pablo N. Delgado, M.D.

PRECEPTOR STATEMENT *(Continued)*

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN *(Continued)*

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheet.) D
P-32 (Sodium)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	Ø	
P-32 (Colloidal)	INTRACAVITARY TREATMENT	Ø	
I-131	TREATMENT OF THYROID CARCINOMA	8	see 8 Jx
	TREATMENT OF HYPERTHYROIDISM	15	
Au-198	INTRACAVITARY TREATMENT	Ø	
Co-60 or Cs-137	INTERSTITIAL TREATMENT	Ø	
	INTRACAVITARY TREATMENT	Ø	
I-125 or Ir-192	INTERSTITIAL TREATMENT	Ø	
Co-60 or Cs-137	TELETHERAPY TREATMENT	Ø	
Sr-90	TREATMENT OF EYE DISEASE	Ø	
	RADIOPHARMACEUTICAL PREPARATION	2	
Mo-99/ Tc-99m	GENERATOR	2	
Sn-113/ In-113m	GENERATOR	Ø	
Tc-99m	REAGENT KITS	1	
Other Sr89	TREATMENT of Bone Pain From	5	

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

LOCATION	DATES	CLOCK HOURS OF EXPERIENCE
November 1990 KUMC	11/1990	200
KUMC	April 1992	200
KUMC	July 1993	200
KUMC	Mar 7 1994	200

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR: David F. Preston

b. NAME OF INSTITUTION: KANSAS UNIV. MED CNTR

c. MAILING ADDRESS: DEPT RADIOLOGY ~~KANSAS UNIV~~

d. CITY: 39th ST @ RAINBOW BLVD KC

e. MATERIALS LICENSE NUMBER: 18-C054-02 exp 6/30/98

5. PRECEPTOR'S SIGNATURE: David F. Preston MD

6. PRECEPTOR'S NAME *(Please type or print)*: DAVID F. PRESTON

7. DATE: 3/5/97

01093806

State of Missouri

Department of Economic Development
Division of Professional Registration
Board of Registration for the Healing Arts

PHYSICIAN AND SURGEON

VALID THROUGH JANUARY 31, 1998
ORIGINAL CERTIFICATE/LICENSE NO. MD 110617

ISSUED: 06/14/96

PABLO N DELGADO M.D.
4400 WORNALL
KANSAS CITY MO 64111

Tina Steinman
EXECUTIVE DIRECTOR

Randall G Singer
DIVISION DIRECTOR

Saint Luke's Hospital of Kansas City
SAINT LUKE'S-SHAWNEE MISSION HEALTH SYSTEM

Winner
1997 National Quality Health Care Award

April 24, 1997

TO: Memorandum for Record

SUBJ: Approval of Pablo N. Delgado, M.D. as an Authorized User for Parts 100 & 200; NRC License No. 24-00889-01

The Radiation Safety Committee has reviewed Dr. Delgado's qualifications as specified in 10 CFR 35, Parts 910, *Training for uptake, dilution, and excretion studies*, and 920, *Training for imaging and localization studies*.

Based on his ABR certification in Diagnostic Radiology, and his State of Missouri Medical License (expires Jan 31, 1998), Dr. Delgado is hereby approved as an authorized user for Parts 100 and 200.

Approval of Dr. Delgado for Part 300, *Use of radiopharmaceuticals for therapy*, must be done through a license amendment. In the interim, Dr. Delgado's use of isotopes specified in Part 300 must be done under the supervision of an authorized user who is approved for Part 300. (Note: Orders or Written Directives for Part 300 use must be countersigned.)

A copy of this approval along with documentation of Dr. Delgado's qualifications must be forwarded to the NRC.

JAMES G. FITZSIMMONS, M.D.
Chairman, Radiation Safety Committee

users.sam

4401 Wornall Road, Kansas City, MO 64111 • (816) 932-2000

Saint Luke's-Shawnee Mission Health System is an Equal Employment Opportunity Employer / Services Provided on a Nondiscriminatory Basis